U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene...

Related Keywords

Michigan ,United States ,Paul Perreault ,Etanjalie Ayala ,Matt Kapusta ,Kim Phelan ,Maria Tortoreto ,Twitter ,Drug Administration ,Laurencea Boxer Research Professor Of Pediatrics ,University Of Michigan ,Operations Communications ,Coalition For Hemophiliab Over ,Behring Pharmacovigilance Department ,Wrd Communications ,Head Of Research Development ,Multichannel News Release ,Executive Officer ,Chief Operating Officer ,Steven Pipe ,Research Professor ,Chief Executive Officer ,Bill Mezzanotte ,Chief Medical Officer ,Annual Bleeding Rate ,Safety Information ,Pharmacovigilance Department ,Csl ,Otc ,Mallcap ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Broadcast Feed Annoucement ,Clinical Trials Amp Medical Discoveries ,Fda Approval ,